Redaporfin
Based on 1 publication(s) in Google Scholar
Redaporfin (LUZ11) acts as a potent photosensitizer. Redaporfin causes direct antineoplastic effects as well as indirect immune-dependent destruction of malignant lesions.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.00%
- CAS No.: 1224104-08-8
- 화학식: C48H38F8N8O8S4
- 분자량:1135.11
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Macrocyclic Compound Library
HY-L041
-
Endoplasmic Reticulum Stress Compound Library
HY-L054
-
Rare Diseases Drug Library
HY-L102
-
Bioactive Compound Library Max
HY-L181
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Redaporfin
More
Biological Activity
The combination photodynamic therapy (PDT) with Redaporfin (5μM) induces a reduction in the abundance of several Golgi apparatus (GA) proteins such as Golgi brefeldin A-resistant guanine nucleotide exchange factor 1 (GBF1), golgin subfamily A member 2 (GOLGA2), and galactosyltransferase 1 (GALT1), as well as that of two ER proteins, eukaryotic translation initiation factor 2-alpha (eIF2α) kinase 3 (EIF2AK3) and protein disulfide-isomerase A3 (PDIA3). In contrast, there is no major decrease in mitochondrial import receptor subunit TOM20 homolog (TOMM20) or in the cytoskeleton protein β-actin[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human osteosarcoma U2OS cells
-
Concentration:0.3, 0.6, 1.3, 2.5, 5, 10 μM
-
Incubation Time:6 hours
-
Result:Induced a reduction in the abundance of GBF1, GOLGA2, and GALT1, as well as EIF2AK3 and PDIA3.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1224104-08-8
-
Appearance Solid
-
분자량 1135.11
-
화학식 C48H38F8N8O8S4
-
Color Brown to black
-
SMILES
O=S(C1=CC=C(F)C(/C2=C3CCC(/C(C4=C(F)C(S(=O)(NC)=O)=CC=C4F)=C5C=C/C(N/5)=C(C6=C(F)C(S(=O)(NC)=O)=CC=C6F)/C(CC/7)=NC7=C(C8=C(F)C(S(=O)(NC)=O)=CC=C8F)/C9=CC=C2N9)=N\3)=C1F)(NC)=O
-
Synonyms
LUZ11; F2BMet
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
용액&용해도
DMSO : 100 mg/mL (88.10 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.20 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (286 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.8810 mL | 4.4049 mL | 8.8097 mL | 22.0243 mL |
| 5 mM | 0.1762 mL | 0.8810 mL | 1.7619 mL | 4.4049 mL | |
| 10 mM | 0.0881 mL | 0.4405 mL | 0.8810 mL | 2.2024 mL | |
| 15 mM | 0.0587 mL | 0.2937 mL | 0.5873 mL | 1.4683 mL | |
| 20 mM | 0.0440 mL | 0.2202 mL | 0.4405 mL | 1.1012 mL | |
| 25 mM | 0.0352 mL | 0.1762 mL | 0.3524 mL | 0.8810 mL | |
| 30 mM | 0.0294 mL | 0.1468 mL | 0.2937 mL | 0.7341 mL | |
| 40 mM | 0.0220 mL | 0.1101 mL | 0.2202 mL | 0.5506 mL | |
| 50 mM | 0.0176 mL | 0.0881 mL | 0.1762 mL | 0.4405 mL | |
| 60 mM | 0.0147 mL | 0.0734 mL | 0.1468 mL | 0.3671 mL | |
| 80 mM | 0.0110 mL | 0.0551 mL | 0.1101 mL | 0.2753 mL |
Redaporfin Related Classifications
HY-17644 Related Classifications
Powered by Bioz